23 completed, 17 active not recruiting, 11 terminated, 7 recruiting. 69 Phase 1, 15 Phase 2.
Follow CTLA-4 Antigen: new trials by email Literature Review of CTLA-4 Antigen trials Research Report on CTLA-4 Antigen
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Adding Anakinra and Tocilizumab to Nivolumab and Ipilimumab for the Treatment of Melanoma Patients 50 Years of Age or Older Anakinra, Biospecimen Collection, Computed Tomography - Melanoma | Phase 1 | Not yet recruiting | University of Southern California | 40 | 2026-11-01 | 2026-09-24 |
| Immunotherapy (Nivolumab and Ipilimumab) With and Without a Live Biotherapeutic Product (EXL01) for the Treatment of Metastatic Renal Cell Cancer Biospecimen Collection, Bone Scan, Computed Tomography - Advanced Clear Cell Renal Cell Carcinoma, Advanced Sarcomatoid Renal Cell Carcinoma | Phase 1 | Recruiting | City of Hope Medical Center | 33 | 2026-03-23 | 2026-07-16 |
| Personalized Vaccine Immunotherapy in Combination With Checkpoint Inhibitor for Treatment of Triple Negative Breast Cancer Ipilimumab, Pembrolizumab, Vaccine Therapy - Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage IA Breast Cancer AJCC v8 | Phase 1 | Recruiting | Emory University | 18 | 2025-12-02 | 2026-01-26 |
| Inulin Gel in Combination With Ipilimumab and Nivolumab for the Treatment of Metastatic or Locally Advanced Kidney Cell Cancer, ICON Trial Biopsy, Biospecimen Collection, Computed Tomography - Locally Advanced Clear Cell Renal Cell Carcinoma, Locally Advanced Sarcomatoid Renal Cell Carcinoma | Phase 1 / Phase 2 | Recruiting | University of Michigan Rogel Cancer Center | 55 | 2025-08-15 | 2026-07-31 |
| Peptide-Pulsed Dendritic Cell Vaccination in Combination With Nivolumab and Ipilimumab for the Treatment of Recurrent and/or Progressive Diffuse Hemispheric Glioma, H3 G34-mutant Dendritic Cell Tumor Peptide Vaccine, Ipilimumab, Leukapheresis - Diffuse Hemispheric Glioma, H3 G34-Mutant | Phase 1 | Withdrawn | Jonsson Comprehensive Cancer Center | 2024-12-01 | 2025-02-24 | |
| Immunotherapy in Combination With Prednisone and Sirolimus for Kidney Transplant Recipients With Unresectable or Metastatic Skin Cancer Biopsy Procedure, Biospecimen Collection, Computed Tomography - Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage III Cutaneous Merkel Cell Carcinoma AJCC v8 | Phase 1 / Phase 2 | Recruiting | National Cancer Institute (NCI) | 16 | 2024-07-24 | 2026-10-14 |
| CBM588 Capsules in Combination With Nivolumab and Ipilimumab for the Treatment of Advanced Stage Kidney Cancer Biospecimen Collection, Bone Scan, CBM588 Capsules - Advanced Clear Cell Renal Cell Carcinoma, Advanced Renal Cell Carcinoma | Phase 1 | Recruiting | Osel, Inc. | 28 | 2024-06-19 | 2024-05-30 |
| Nivolumab and Ipilimumab With and Without Camu Camu for the Treatment of Patients With Metastatic Renal Cell Carcinoma Biospecimen Collection, Bone Scan, Computed Tomography - Clear Cell Renal Cell Carcinoma, Sarcomatoid Renal Cell Carcinoma | Phase 1 | Suspended | City of Hope Medical Center | 31 | 2023-10-06 | 2026-10-08 |
| Stereotactic Radiosurgery and Immune Checkpoint Inhibitors With NovoTTF-200M for the Treatment of Melanoma Brain Metastases Ipilimumab, Nivolumab, Pembrolizumab - Clinical Stage IV Cutaneous Melanoma AJCC v8, Melanoma of Unknown Primary | Phase 1 | Terminated | Emory University | 1 | 2022-10-13 | 2026-04-23 |
| Ipilimumab, Ibrutinib, and Nivolumab for the Treatment of Chronic Lymphocytic Leukemia and Richter Transformation Ibrutinib, Ipilimumab, Nivolumab - Hematopoietic and Lymphoid Cell Neoplasm, Recurrent Chronic Lymphocytic Leukemia | Phase 1 | Withdrawn | M.D. Anderson Cancer Center | 2022-07-14 | 2025-02-28 | |
| Testing the Combination of ZEN003694 and Nivolumab With or Without Ipilimumab in Solid Tumors BET Bromodomain Inhibitor ZEN-3694, Biopsy Procedure, Biospecimen Collection - Metastatic Malignant Solid Neoplasm, Recurrent Malignant Solid Neoplasm | Phase 1 | Suspended | National Cancer Institute (NCI) | 66 | 2022-02-02 | 2026-08-17 |
| Intralesional Influenza Vaccine for the Treatment of Stage I-IV Melanoma Ipilimumab, Nivolumab, Pembrolizumab - Clinical Stage I Cutaneous Melanoma AJCC v8, Clinical Stage IA Cutaneous Melanoma AJCC v8 | Phase 1 | Recruiting | Carlo Contreras | 36 | 2021-10-20 | 2026-07-13 |
| Ipilimumab and Nivolumab for the Treatment of Stage III-IV Unresectable Metastatic Melanoma Ipilimumab, Nivolumab, Lymph Node Assessment - Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC v8 | Phase 1 | Terminated | Mayo Clinic | 6 | 2021-09-16 | 2024-12-10 |
| Testing the Combination of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) in Children, Adolescent, and Young Adult Patients With Relapsed/Refractory Cancers That Have an Increased Number of Genetic Changes, The 3CI Study Biospecimen Collection, Ipilimumab, Nivolumab - Constitutional Mismatch Repair Deficiency Syndrome, Hematopoietic and Lymphoid Cell Neoplasm | Phase 1 | Withdrawn | National Cancer Institute (NCI) | 2021-05-11 | 2026-06-10 | |
| DS3201 and Ipilimumab for the Treatment of Metastatic Prostate, Urothelial and Renal Cell Cancers Ipilimumab, Valemetostat - Aggressive Variant Prostate Carcinoma, Castration-Resistant Prostate Carcinoma | Phase 1 | Active not recruiting | M.D. Anderson Cancer Center | 65 | 2020-08-20 | 2026-05-20 |
| Safety and Efficacy of Combination Osimertinib and Ipilimumab in Patients w EGFR Mutated NSCLC Ipilimumab, Osimertinib - Non-Small Cell Lung Cancer With Mutation in Epidermal Growth Factor Receptor (Disorder) | Phase 1 | Active not recruiting | University of Utah | 24 | 2020-08-20 | 2026-05-19 |
| Testing the Addition of an Anti-cancer Drug, Copanlisib, to the Usual Immunotherapy (Nivolumab With or Without Ipilimumab) in Patients With Advanced Solid Cancers That Have Changes in the Following Genes: PIK3CA and PTEN Biopsy Procedure, Biospecimen Collection, Computed Tomography - Advanced Malignant Solid Neoplasm, Metastatic Malignant Solid Neoplasm | Phase 1 / Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 54 | 2020-07-17 | 2026-10-27 |
| Regorafenib, Ipilimumab and Nivolumab for the Treatment of Chemotherapy Resistant Microsatellite Stable Metastatic Colorectal Cancer Ipilimumab, Nivolumab, Regorafenib - Advanced Colon Adenocarcinoma, Metastatic Colon Adenocarcinoma | Phase 1 | Completed | City of Hope Medical Center | 39 | 2020-05-27 | 2026-01-28 |
| Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial Abemaciclib, Abiraterone, Afatinib - Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Anatomic Stage IV Breast Cancer AJCC v8 | Phase 1 | Terminated | OHSU Knight Cancer Institute | 2 | 2020-04-01 | 2024-03-04 |
| Testing the Combination of Anetumab Ravtansine With Either Nivolumab, Nivolumab and Ipilimumab, or Gemcitabine and Nivolumab in Advanced Pancreatic Cancer Anetumab Ravtansine, Biopsy Procedure, Biospecimen Collection - Pancreatic Adenocarcinoma, Stage II Pancreatic Cancer AJCC v8 | Phase 1 | Active not recruiting | National Cancer Institute (NCI) | 74 | 2019-12-09 | 2026-07-21 |
Showing 20 of 69. Sign in to see all of them.
Melanoma (15) · Neoplasm Metastasis (10) · Carcinoma, Renal Cell (8) · Leukemia, Lymphocytic, Chronic, B-Cell (7) · Leukemia, Myeloid, Acute (7) · Lymphoma, Non-Hodgkin (6) · Hematologic Neoplasms (5) · Hodgkin Disease (5) · Myelodysplastic Syndromes (5) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (5) · Breast Neoplasms (4) · Burkitt Lymphoma (4) · Carcinoma, Non-Small-Cell Lung (4) · Clear-cell metastatic renal cell carcinoma (4) · Lymphoma, Follicular (4)
National Cancer Institute (NCI) (29) · M.D. Anderson Cancer Center (10) · City of Hope Medical Center (5) · Emory University (5) · Jonsson Comprehensive Cancer Center (3) · Shanghai Cell Therapy Research Institute (2) · Carlo Contreras (1) · Claire Verschraegen (1) · Fred Hutchinson Cancer Center (1) · Innovent Biologics (Suzhou) Co. Ltd. (1) · Mayo Clinic (1) · Northwestern University (1) · OHSU Knight Cancer Institute (1) · Osel, Inc. (1) · Robert Lowsky (1)
United States (63) · Canada (5) · China (3) · Australia (1)
Sumanta K Pal (3) · Evan J Lipson (2) · Huajun Jin, Ph.D (2) · Jiangtao Wang (2) · Qijun Qian, Ph.D (2) · Yan Sun (2) · Zhiwei Zhang, Ph.D (2) · A P Chen (1) · Adam Dicker, MD (1) · Alex Chehrazi-Raffle, MD (1) · Amir A Jazaeri (1) · Ana Aparicio (1) · Anastasios Dimou, M.D. (1) · Andrea B Apolo (1) · Anna Spreafico (1)
PMID 18523152, PMID 18974373, PMID 27269940, PMID 27410923, PMID 28428884, PMID 29490632, PMID 31401903, PMID 32192573, PMID 32376721, PMID 32478814, PMID 32503950, PMID 32816895, PMID 32853585, PMID 32915679, PMID 33677480, PMID 33720354, PMID 33909232, PMID 34032893, PMID 34562230, PMID 34780125, PMID 34965890, PMID 35031545, PMID 35091445, PMID 35228755, PMID 35470301, PMID 35622074, PMID 36464584, PMID 36706355, PMID 36821617, PMID 36892833, PMID 37129197, PMID 37505794, PMID 37621406, PMID 37962072, PMID 38252910, PMID 38471508, PMID 38497709, PMID 38737792, PMID 38874333, PMID 38934093, PMID 38954785, PMID 39384194, PMID 39816915, PMID 39863139, PMID 39945382, PMID 41662628
P30CA033572 (5), UM1CA186691 (5), P30CA138292 (4), UM1CA186704 (4), UM1CA186709 (3), UM1CA186717 (3), P30CA006516 (2), P30CA016672 (2), U01CA062490 (2), U10CA180868 (2), UM1CA186688 (2), UM1CA186689 (2), UM1CA186690 (2), ZIABC011078 (2), K12CA076930 (1)